Literature DB >> 30264880

Donor-derived infections and infectious risk in xenotransplantation and allotransplantation.

Anoma Nellore1, Jay A Fishman2.   

Abstract

Post-transplantation infections are common in allograft recipients and should be expected in all immunocompromised hosts. Based on the need for immunosuppression in xenotransplantation, procedures developed to enhance safety in allotransplantation can be applied in future xenotransplantation clinical trials. Standardized approaches can be developed to guide the evaluation of common infectious syndromes in xenograft recipients. The opportunity created by screening of swine intended as xenograft donors has equal applicability to allotransplantation-notably broader screening strategies for allograft donors such as use of advanced sequencing modalities including broad-range molecular probes, microarrays, and high-throughput pyrosequencing. Considerations in management of allotransplant- and xenotransplant-associated infections are largely the same. Experience in xenotransplantation will continue to inform thinking regarding donor-derived infections in allotransplantation. We expect that experience in managing complex allotransplant recipients will similarly inform clinical trials in xenotransplantation.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  clincial trials; donor screening; donor-derived infections; infection; virus

Mesh:

Year:  2018        PMID: 30264880     DOI: 10.1111/xen.12423

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  3 in total

Review 1.  Progress in xenotransplantation: overcoming immune barriers.

Authors:  Megan Sykes; David H Sachs
Journal:  Nat Rev Nephrol       Date:  2022-10-05       Impact factor: 42.439

Review 2.  Transplanting organs from pigs to humans.

Authors:  Megan Sykes; David H Sachs
Journal:  Sci Immunol       Date:  2019-11-01

Review 3.  Virus Safety of Xenotransplantation.

Authors:  Joachim Denner
Journal:  Viruses       Date:  2022-08-30       Impact factor: 5.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.